brilliant Blue G 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5359 | 6104-58-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 20, 2019 | FDA | DUTCH OPHTHALMIC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000175533 | Dyes |
| FDA EPC | N0000194020 | Disclosing Agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Staining method | indication | 127790008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.61 | Basic |
| pKa2 | 7.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.025% | TISSUEBLUE | DUTCH OPHTHALMIC | N209569 | Dec. 20, 2019 | RX | SOLUTION | OPHTHALMIC | Dec. 20, 2024 | NEW CHEMICAL ENTITY |
| 0.025% | TISSUEBLUE | DUTCH OPHTHALMIC | N209569 | Dec. 20, 2019 | RX | SOLUTION | OPHTHALMIC | Dec. 20, 2026 | INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| P2X purinoceptor 7 | Ion channel | ANTAGONIST | IC50 | 8 | IUPHAR | ||||
| Alpha-synuclein | Transporter | IC50 | 5.27 | CHEMBL | |||||
| P2X purinoceptor 7 | Ion channel | IC50 | 6.96 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEMBL4173394 | ChEMBL_ID |
| D10799 | KEGG_DRUG |
| 4147 | IUPHAR_LIGAND_ID |
| DB15594 | DRUGBANK_ID |
| 014584 | NDDF |
| 4039525 | VANDF |
| C0056270 | UMLSCUI |
| 6324599 | PUBCHEM_CID |
| 1998867 | RXNORM |
| 333643 | MMSL |
| 38372 | MMSL |
| M1ZRX790SI | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TISSUEBLUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68803-722 | INJECTION, SOLUTION | 0.01 mg | INTRAOCULAR | NDA | 19 sections |
| TISSUEBLUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68803-722 | INJECTION, SOLUTION | 0.01 mg | INTRAOCULAR | NDA | 19 sections |